中文

Events

China IND Approval Granted for Doer Biologics' DR30206 for Injection in Combination with Standard Chemotherapy for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

2026/10/13

Read more

First Patient Dosed in Phase II Clinical Study of Doer Biologics' DR10624 for the Treatment of Moderate Hypertriglyceridemia Complicated with Diabetic Kidney Disease

2026/10/09

Read more

Doer Biologics Completes First Patient Enrollment in Two Phase 3 Clinical Trials of DR10624 for Severe Hypertriglyceridemia

2026/09/08

Read more

Doer Biologics Announces First Subject Dosed in Phase Ib Trial of DR30206 in Combination with Standard Chemotherapy for NSCLC

2026/09/04

Read more

DR10624 Selected for the 2026 National Science and Technology Major Project "Innovative Drug Development for Heart Failure" – Project Kick-off Meeting Successfully Held

2026/08/13

Read more

Doer Biologics' Global First-in-Class Triple Agonist DR10624 Receives China IND Approval for HFpEF/HFrEF

2026/07/14

Read more

EASL 2026 | Doer Biologics Presents Results from a Phase 2 Study of DR10624 in Severe Hypertriglyceridemia on Liver Fat and Improvement of Hepatic Metabolic Markers

2026/05/28

Read more

AACR 2026｜Doer Bio Presents DR319-DP, a Bispecific Bipayload ADC, Demonstrating Breakthrough Potential in Overcoming Efficacy and Resistance Challenges in Solid Tumors

2026/05/25

Read more

Doer Biologics Honored as Hangzhou Quasi-Unicorn for Sixth Consecutive Year

2026/04/24

Read more

AACR 2026 | Doer Biologics Presents Preclinical Data on Bispecific Dual-Payload ADC

2026/04/16

Read more